Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society..
BACKGROUND: Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2-inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF patients unexposed to RUX.
METHODS: The authors investigated the incidence of BP in 886 RUX-treated MF patients, included in the "RUX-MF" retrospective study.
RESULTS: The BP incidence rate ratio (IRR) was 3.74 per 100 patient-years (3.74 %p-y). At therapy start, Common Terminology Criteria for Adverse Events grade 3-4 anemia (hemoglobin [Hb] <8 g/dL) and severe sex/severity-adjusted anemia (Hb <8/<9 g/dL in women/men) were present in 22.5% and 25% patients, respectively. IRR of BP was 2.34 in patients with no baseline anemia and reached respectively 4.22, 4.89, and 4.93 %p-y in patients with grade 1, 2, and 3-4 anemia. Considering the sex/severity-adjusted Hb thresholds, IRR of BP was 2.85, 4.97, and 4.89 %p-y in patients with mild/no anemia, moderate, and severe anemia. Transfusion-dependent patients had the highest IRR (5.03 %p-y). Progression-free survival at 5 years was 70%, 52%, 43%, and 27% in patients with no, grade 1, 2, and 3-4 anemia, respectively (p < .001). At 6 months, 260 of 289 patients with no baseline anemia were receiving ruxolitinib, and 9.2% had developed a grade 3-4 anemia. By 6-month landmark analysis, BP-free survival was significantly worse in patients acquiring grade 3-4 anemia (69.3% vs. 88.1% at 5 years, p < .001).
CONCLUSIONS: This study highlights that anemia correlates with an increased risk of evolution into BP, both when present at baseline and when acquired during RUX monotherapy. Innovative anemia therapies and disease-modifying agents are warranted in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Cancer - 130(2024), 8 vom: 15. März, Seite 1270-1280 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
82S8X8XX8H |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.35156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366444719 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366444719 | ||
| 003 | DE-627 | ||
| 005 | 20240319232423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.35156 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM366444719 | ||
| 035 | |a (NLM)38153814 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Palandri, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. | ||
| 520 | |a BACKGROUND: Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2-inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF patients unexposed to RUX | ||
| 520 | |a METHODS: The authors investigated the incidence of BP in 886 RUX-treated MF patients, included in the "RUX-MF" retrospective study | ||
| 520 | |a RESULTS: The BP incidence rate ratio (IRR) was 3.74 per 100 patient-years (3.74 %p-y). At therapy start, Common Terminology Criteria for Adverse Events grade 3-4 anemia (hemoglobin [Hb] <8 g/dL) and severe sex/severity-adjusted anemia (Hb <8/<9 g/dL in women/men) were present in 22.5% and 25% patients, respectively. IRR of BP was 2.34 in patients with no baseline anemia and reached respectively 4.22, 4.89, and 4.93 %p-y in patients with grade 1, 2, and 3-4 anemia. Considering the sex/severity-adjusted Hb thresholds, IRR of BP was 2.85, 4.97, and 4.89 %p-y in patients with mild/no anemia, moderate, and severe anemia. Transfusion-dependent patients had the highest IRR (5.03 %p-y). Progression-free survival at 5 years was 70%, 52%, 43%, and 27% in patients with no, grade 1, 2, and 3-4 anemia, respectively (p < .001). At 6 months, 260 of 289 patients with no baseline anemia were receiving ruxolitinib, and 9.2% had developed a grade 3-4 anemia. By 6-month landmark analysis, BP-free survival was significantly worse in patients acquiring grade 3-4 anemia (69.3% vs. 88.1% at 5 years, p < .001) | ||
| 520 | |a CONCLUSIONS: This study highlights that anemia correlates with an increased risk of evolution into BP, both when present at baseline and when acquired during RUX monotherapy. Innovative anemia therapies and disease-modifying agents are warranted in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anemia | |
| 650 | 4 | |a blast phase | |
| 650 | 4 | |a myelofibrosis | |
| 650 | 4 | |a ruxolitinib | |
| 650 | 7 | |a ruxolitinib |2 NLM | |
| 650 | 7 | |a 82S8X8XX8H |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Hemoglobins |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 700 | 1 | |a Palumbo, Giuseppe A |e verfasserin |4 aut | |
| 700 | 1 | |a Benevolo, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Iurlo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Elli, Elena M |e verfasserin |4 aut | |
| 700 | 1 | |a Abruzzese, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Polverelli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Tiribelli, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Auteri, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Tieghi, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Caocci, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Binotto, Gianni |e verfasserin |4 aut | |
| 700 | 1 | |a Cavazzini, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Branzanti, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Beggiato, Eloise |e verfasserin |4 aut | |
| 700 | 1 | |a Miglino, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Bosi, Costanza |e verfasserin |4 aut | |
| 700 | 1 | |a Crugnola, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Bocchia, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Novella |e verfasserin |4 aut | |
| 700 | 1 | |a Scaffidi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Venturi, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Duminuco, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Isidori, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Krampera, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Pane, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Cilloni, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Semenzato, Gianpietro |e verfasserin |4 aut | |
| 700 | 1 | |a Lemoli, Roberto M |e verfasserin |4 aut | |
| 700 | 1 | |a Cuneo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Trawinska, Malgorzata M |e verfasserin |4 aut | |
| 700 | 1 | |a Vianelli, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Cavo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Bonifacio, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 130(2024), 8 vom: 15. März, Seite 1270-1280 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g number:8 |g day:15 |g month:03 |g pages:1270-1280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.35156 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |e 8 |b 15 |c 03 |h 1270-1280 | ||